Commentary: Blanket-licensing deals may hurt biotech growth

09/15/2008 | Boston Herald

The Massachusetts Life Sciences Initiative includes a provision that, if unresolved, could discourage academic scientists from spinning out new firms and could limit venture capital investments, Alnylam Pharmaceuticals CEO John Maraganore and Polaris Venture Partners' Amir Nashat wrote in a Boston Herald commentary. The provision allows blanket-licensing agreements that award a single company access to patents derived from publicly funded research conducted at educational institutions in the state.

View Full Article in:

Boston Herald

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN